Citadel Advisors
ASMB icon

Citadel Advisors’s Assembly Biosciences ASMB Stock Holding History

Citadel Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$706K Sell
25,437
-7,429
-23% -$212K ﹤0.01% 8475
2025
Q4 		$1.12M Sell
32,866
-21,012
-39% -$677K ﹤0.01% 7154
2025
Q3 		$1.38M Buy
53,878
+18,153
+51% +$398K ﹤0.01% 6842
2025
Q2 		$647K Buy
35,725
+23,467
+191% +$310K ﹤0.01% 8018
2025
Q1 		$117K Buy
+12,258
New +$160K ﹤0.01% 11244
2024
Q4 		– Sell
-12,720
Closed -$193K – 14465
2024
Q3 		$193K Sell
12,720
-26
-0.2% -$396 ﹤0.01% 10209
2024
Q2 		$175K Buy
+12,746
New +$182K ﹤0.01% 10126
2024
Q1 		– Sell
-10,410
Closed -$102K – 14513
2023
Q4 		$102K Sell
10,410
-1,137
-10% -$10.8K ﹤0.01% 10908
2023
Q3 		$123K Buy
11,547
+3,743
+48% +$45.1K ﹤0.01% 10635
2023
Q2 		$108K Sell
7,804
-3,942
-34% -$48.4K ﹤0.01% 10821
2023
Q1 		$118K Buy
11,746
+2,683
+30% +$45.3K ﹤0.01% 11018
2022
Q4 		$141K Buy
9,063
+6,781
+297% +$116K ﹤0.01% 10699
2022
Q3 		$45K Sell
2,282
-11,632
-84% -$281K ﹤0.01% 11699
2022
Q2 		$351K Buy
13,914
+12,204
+714% +$281K ﹤0.01% 9451
2022
Q1 		$42K Sell
1,710
-425
-20% -$9.12K ﹤0.01% 12905
2021
Q4 		$60K Sell
2,135
-68,392
-97% -$2.24M ﹤0.01% 13138
2021
Q3 		$2.94M Buy
70,527
+2,803
+4% +$117K ﹤0.01% 5403
2021
Q2 		$3.15M Sell
67,724
-6,029
-8% -$299K ﹤0.01% 5476
2021
Q1 		$4.07M Buy
73,753
+7,278
+11% +$482K ﹤0.01% 4718
2020
Q4 		$4.83M Sell
66,475
-26,064
-28% -$3.06M ﹤0.01% 3749
2020
Q3 		$18.3M Sell
92,539
-4,242
-4% -$1.07M 0.01% 1660
2020
Q2 		$27.1M Buy
96,781
+3,160
+3% +$737K 0.01% 1238
2020
Q1 		$16.7M Buy
93,621
+9,752
+12% +$2.09M 0.01% 1381
2019
Q4 		$20.6M Buy
83,869
+45,159
+117% +$8.32M 0.01% 1448
2019
Q3 		$4.57M Buy
38,710
+1,184
+3% +$179K ﹤0.01% 3240
2019
Q2 		$6.08M Buy
37,526
+19,080
+103% +$3.63M ﹤0.01% 2814
2019
Q1 		$4.36M Buy
18,446
+10,338
+128% +$2.62M ﹤0.01% 3201
2018
Q4 		$2.2M Buy
+8,108
New +$2.35M ﹤0.01% 3997
2018
Q3 		– Sell
-1,772
Closed -$830K – 9177
2018
Q2 		$833K Buy
+1,772
New +$937K ﹤0.01% 5528
2018
Q1 		– Sell
-1,049
Closed -$650K – 8248
2017
Q4 		$569K Buy
+1,049
New +$475K ﹤0.01% 5450
2014
Q3 		– Sell
-234
Closed -$18K – 8091
2014
Q2 		$18K Sell
234
-1,269
-84% -$90K ﹤0.01% 7340
2014
Q1 		$115K Buy
+1,503
New +$234K ﹤0.01% 6064

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Citadel Advisors's ASMB Position: Q1 2026 in Review

Citadel Advisors reduced its Assembly Biosciences (ASMB) stake by 23% in Q1 2026, selling an estimated $212K and leaving 25,437 shares worth $706K. The position accounts for ﹤0.01% of the portfolio, ranked #8475.

Citadel Advisors first reported a position in ASMB in Q1 2014 and has held it in 32 quarters since. The position peaked at $27.1M in Q2 2020. 75 funds tracked by Wall St. Rank hold ASMB as of Q1 2026.

  • Citadel Advisors held 25,437 shares of Assembly Biosciences worth $706K as of Q1 2026.
  • Citadel Advisors sold 7,429 Assembly Biosciences shares in Q1 2026, an estimated $212K.
  • Assembly Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8475 holding.
  • Citadel Advisors first reported a position in Assembly Biosciences in Q1 2014 and has held it in 32 quarters since.
  • Citadel Advisors's Assembly Biosciences position peaked at $27.1M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.